FisioReact continues to expand in Spain. The Catalan company specializing in physiotherapy services at home plans to enter the markets of Seville, Malaga, and Bilbao in 2023, according to Albert Valls, founder, and CEO of FisioReact.
For now, the Barcelona-based company is present in the Catalan capital, Madrid, Valencia, and will shortly arrive in Seville. In 2022, the company billed €505,000, compared to €300,000 in 2021, and the goal for 2023 is to earn €1.1 million, which would double its turnover.
The home physiotherapy company has increased the number of sessions in the last year, both for individuals and companies. Specifically, in 2022 FisioReact carried out 15,587 physiotherapy and rehabilitation sessions, 178% more than in 2021.
Throughout 2002, the company has also increased the number of new patients, 78.6% more, with a total of 2,638 users and, consequently, the number of professionals, which have gone from fifteen employees in 2021 to 85 employees in the last year. The goal for 2023 is to reach 120 professionals, according to Valls.
Read more about FisioReact and find the most important financial news of the day with our companion app Born2Invest, available for free for both Android and iOS devices.
FisioReact aims to make the international leap from 2025
Although it is still early according to the founder of FisioReact, the company hopes to bring its services to all of Spain in 2024 and to begin its international adventure by 2025, choosing Italy as its first destination abroad.
Founded in 2018 by Marc Valls and Albert Valls from Barcelona, FisioReact’s main activity is to offer physiotherapy services at home for both companies and individuals. The company has expert physiotherapists in the specialties of neurological, pediatric, pregnant, back pain/decontracting and rehabilitation, and sports physiotherapy.
FisioReact agreement with Qida for the care of the elderly
Although at FisioReact they have been working for companies from multiple sectors for years, the collaboration agreements that they have been closing with some of the health sectors stand out. Among foundations, hospitals and residences is the alliance with Qida for the care of the elderly, which has allowed them to reach dependent patients who require a comprehensive and high-quality care service.
The company has also closed agreements with hospital centers which, in the case of Barcelona, are the Corachan Clinic and the El Pilar Hospital, for which it provides home physiotherapy services for patients. Likewise, the operator has a collaborative relationship with the Dexeus University Hospital, through the Catalan Institute of Sports Traumatology and Medicine (Icatme).
The company closed its first round of private financing in 2022, raising €400,000
At the beginning of 2022, the company closed its first round of private financing, with which it obtained €400,000, an operation that was led by several Catalan business angels, whose names were not disclosed.
The company is controlled by Albert Valls and the capital also includes Juan Víctor Izquierdo, former head of marketing at Indy and former CEO of Jungle Prize, and Román Riera, a professional with experience in the world of consulting at PwC and EY.
DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.
This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.
First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.
Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.
Interest for Bitcoin Returns: Demand Outstrips Supply Again
With demand pushing Bitcoin above $27,000, the price closed September above a bullish metric. This is the 20-period simple moving...
How Colombia Is Advancing in the Use of Medical Cannabis
In Latin America, in addition to Colombia, Peru, Argentina, Brazil, and Chile also have other regulations that have given a...
Deagle Launches Crowdfunding for SEM, First Transportable Renewable Energy Production System
To fund its first SEMs, Deagle has launched an equity crowdfunding campaign on Ecomill.it, the first Italian platform to facilitate...
Ideas of Weaker Cotton Demand Due to Economic Problems in Asia Continue
Cotton closed higher last week on ideas of smaller US crops that should be seen in the USDA data that...
ClubDealOnline: Net Income in Q1, Higher Than in the Whole of 2022
For the future, in addition to continuing to support cutting-edge startups on their growth path, the platform ClubDealOnline is increasingly...
Biotech2 weeks ago
AbolerIS Pharma Closes a Round of €27 Million Led by Caixa Capital
Business1 day ago
Using Dow Jones Daily Volatility to Time Entry and Exit Points
Business1 week ago
Current Woes in Bonds Promise Future Grief for Stocks: Focus on Dow Jones
Biotech6 days ago
Jazz Pharmaceuticals’ Leukemia Drug Receives European Commission Approval